Total Liver Function Research Articles

Robotic Surgery Twice Performed in the Treatment of Hilar Cholangiocarcinoma With Deep Jaundice

To explore and find a new method to treat hilar cholangiocarcinoma with deep jaundice assisted by Da Vinci robot. A hilar cholangiocarcinoma patient of type Bismuch-Corlette IIIa was found with deep jaundice (total bilirubin: 635 µmol/L). On the first admission, we performed Da Vinci robotic surgery including drainage of left hepatic duct, dissection of right hepatic vessels (right portal vein and right hepatic artery), and placement of right-hepatic vascular control device. Three weeks later on the second admission when the jaundice disappeared we occluded right-hepatic vascular discontinuously for 6 days and then sustained later. On the third admission after 3 weeks of right-hepatic vascular control, the right hemihepatectomy was performed by Da Vinci robot for the second time. The future liver remnant after the right-hepatic vascular control increased from 35% to 47%. The volume of left lobe increased by 368 mL. When the total bilirubin and liver function were all normal, right hemihepatectomy was performed by Da Vinci robot 10 weeks after the first operation. The removal of atrophic right hepatic lobe with tumor in bile duct was found with no pathologic cancer remaining in the margin. The patient was followed up at our outpatient clinic every 3 months and no tumor recurrence occurs by now (1 y). Under the Da Vinci robotic surgical system, a programmed treatment can be achieved: first, the hepatic vessels were controlled gradually together with biliary drainage, which results in liver's partial atrophy and compensatory hypertrophy in the other part. Then a radical hepatectomy could be achieved. Such programmed hepatectomy provides a new treatment for patients of hilar cholangiocarcinoma with deep jaundice who have the possibility of radical heptolobectomy.

Monitoring of Total and Regional Liver Function after SIRT

Selective internal radiation therapy (SIRT) is a promising treatment modality for advanced hepatocellular carcinoma or metastatic liver cancer. SIRT is usually well tolerated. However, in most patients, SIRT will result in a (temporary) decreased liver function. Occasionally patients develop radioembolization-induced liver disease (REILD). In case of a high tumor burden of the liver, it could be beneficial to perform SIRT in two sessions enabling the primary untreated liver segments to guarantee liver function until function in the treated segments has recovered or functional hypertrophy has occurred. Clinically used liver function tests provide evidence of only one of the many liver functions, though all of them lack the possibility of assessment of segmental (regional) liver function. Hepatobiliary scintigraphy (HBS) has been validated as a tool to assess total and regional liver function in liver surgery. It is also used to assess segmental liver function before and after portal vein embolization. HBS is considered as a valuable quantitative liver function test enabling assessment of segmental liver function recovery after regional intervention and determination of future remnant liver function. We present two cases in which HBS was used to monitor total and regional liver function in a patient after repeated whole liver SIRT complicated with REILD and a patient treated unilaterally without complications.

Dynamic gadoxetate‐enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis

To evaluate dynamic hepatocyte-specific contrast-enhanced MRI (DHCE-MRI) for the assessment of global and segmental liver volume and function in patients with primary sclerosing cholangitis (PSC), and to explore the heterogeneous distribution of liver function in this patient group. Twelve patients with primary sclerosing cholangitis (PSC) and 20 healthy volunteers were examined using DHCE-MRI with Gd-EOB-DTPA. Segmental and total liver volume were calculated, and functional parameters (hepatic extraction fraction [HEF], input relative blood-flow [irBF], and mean transit time [MTT]) were calculated in each liver voxel using deconvolutional analysis. In each study subject, and incongruence score (IS) was constructed to describe the mismatch between segmental function and volume. Among patients, the liver function parameters were correlated to bile duct obstruction and to established scoring models for liver disease. Liver function was significantly more heterogeneously distributed in the patient group (IS 1.0 versus 0.4). There were significant correlations between biliary obstruction and segmental functional parameters (HEF rho -0.24; irBF rho -0.45), and the Mayo risk score correlated significantly with the total liver extraction capacity of Gd-EOB-DTPA (rho -0.85). The study demonstrates a new method to quantify total and segmental liver function using DHCE-MRI in patients with PSC.

Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12‐month safety report

Hypogonadism, which is highly prevalent in men with sickle cell disease (SCD), affects quality of life and causes great morbidity. The safety of testosterone replacement therapy (TRT) in SCD in relation to priapism episodes is relatively unknown. Our aim was to monitor the safety of TRT in a cohort of seven hypogonadal men with SCD. Testosterone undecanoate (Nebido) 1 g was administered intramuscularly to adult men with homozygous SCD (Hb SS) having hypogonadism [serum total testosterone ≤12.0 nmol/L (346 ng/dL), reference range 12.5-38.1 nmol/L (360-1098 ng/dL)] for 12 months. Serum total testosterone, haemoglobin, haematocrit, renal and liver function tests, glucose and PSA measurements were done at baseline and 12-month follow-up. Trough serum total testosterone, haemoglobin and haematocrit were measured three monthly. Priapism events and adverse drug events were assessed every 3 months. International Index of Erectile Function (IIEF), Androgen Deficiency in the Ageing Male (ADAM) and World Health Organization Quality of Life (WHOQOL) questionnaires were administered at baseline, 6 and 12 months. Seven men with a mean age of 34.4 years were treated. Median total testosterone increased from 10.6 to 11.2 nmol/L (p = 0.46). Median serum lactate dehydrogenase levels decreased from 1445 to 1143.5 IU/L (p < 0.05), while all other laboratory indices remained stable. Injection site pain was the most frequently reported adverse event, with no increases in painful crises, hypersensitivity or oedema. After TRT, there was no significant increase in priapism frequency. Median questionnaire scores were increased for the IIEF (46-68, p = 0.018), reduced for ADAM (5.0-2.0, p = 0.016) and unchanged for WHOQOL (98-103, p = 0.086). TRT using testosterone undecanoate with eugonadal intent for hypogonadism appears to be safe in men with SCD. This treatment does not appear to promote priapism occurrences and rather it possibly improves sexual function. Future prospective evaluations in larger groups of hypogonadal men with SCD are necessary to confirm these findings.

Antioxidant Potential of a Polyherbal Antimalarial as an Indicator of Its Therapeutic Value

Nefang is a polyherbal product composed of Mangifera indica (bark and leaf), Psidium guajava, Carica papaya, Cymbopogon citratus, Citrus sinensis, and Ocimum gratissimum (leaves), used for the treatment of malaria. Compounds with antioxidant activity are believed to modulate plasmodial infection. Antioxidant activity of the constituent aqueous plants extracts, in vitro, was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH), total phenolic content (TPC), and ferric reducing antioxidant power (FRAP) methods and, in vivo, Nefang (100 and 500 mg kg−1) activity was evaluated in carbon tetrachloride-induced oxidative stressed Wistar rats. Superoxide dismutase, catalase activities, and lipid peroxidation by the malondialdehyde and total proteins assays were carried out. P. guajava, M. indica leaf, and bark extracts had the highest antioxidant properties in all three assays, with no statistically significant difference. Rats treated with the carbon tetrachloride had a statistically significant decrease in levels of triglycerides, superoxide dismutase, and catalase (P < 0.05) and increase in malondialdehyde activity, total protein levels, and liver and renal function markers, whereas rats treated with Nefang showed increased levels in the former and dose-dependent decrease towards normal levels in the later. These results reveal the constituent plants of Nefang that contribute to its in vivo antioxidant potential. This activity is a good indication of the therapeutic potential of Nefang.

Physiological and Biochemical Basis of Clinical Liver Function Tests

To review the literature on the most clinically relevant and novel liver function tests used for the assessment of hepatic function before liver surgery. Postoperative liver failure is the major cause of mortality and morbidity after partial liver resection and develops as a result of insufficient remnant liver function. Therefore, accurate preoperative assessment of the future remnant liver function is mandatory in the selection of candidates for safe partial liver resection. A MEDLINE search was performed using the key words "liver function tests," "functional studies in the liver," "compromised liver," "physiological basis," and "mechanistic background," with and without Boolean operators. Passive liver function tests, including biochemical parameters and clinical grading systems, are not accurate enough in predicting outcome after liver surgery. Dynamic quantitative liver function tests, such as the indocyanine green test and galactose elimination capacity, are more accurate as they measure the elimination process of a substance that is cleared and/or metabolized almost exclusively by the liver. However, these tests only measure global liver function. Nuclear imaging techniques ((99m)Tc-galactosyl serum albumin scintigraphy and (99m)Tc-mebrofenin hepatobiliary scintigraphy) can measure both total and future remnant liver function and potentially identify patients at risk for postresectional liver failure. Because of the complexity of liver function, one single test does not represent overall liver function. In addition to computed tomography volumetry, quantitative liver function tests should be used to determine whether a safe resection can be performed. Presently, (99m)Tc-mebrofenin hepatobiliary scintigraphy seems to be the most valuable quantitative liver function test, as it can measure multiple aspects of liver function in, specifically, the future remnant liver.

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial

BackgroundHepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation. A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage). Transarterial loco regional treatment modalities offer palliative treatment options for these patients; transarterial chemoembolization (TACE) is the current standard treatment. During TACE, a catheter is advanced into the branches of the hepatic artery supplying the tumor, and a combination of embolic material and chemotherapeutics is delivered through the catheter directly into the tumor. Yttrium-90 radioembolization (90Y-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor. 90Y-RE is increasingly used in clinical practice for treatment of intermediate stage hepatocellular carcinoma, but its efficacy has never been prospectively compared to that of the standard treatment (TACE). In this study, we describe the protocol of a multicenter randomized controlled trial aimed at comparing the effectiveness of TACE and 90Y-RE for treatment of patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma.Methods/designIn this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group performance status 0 to 1 and Child-Pugh A to B will be randomly assigned to either 90Y-RE or TACE with drug eluting beads. Patients assigned to 90Y-RE will first receive a diagnostic angiography, followed by the actual transarterial treatment, which can be divided into two sessions in case of bilobar disease. Patients assigned to TACE will receive a maximum of three consecutive transarterial treatment sessions. Patients will undergo structural follow-up for a timeframe of two years post treatment. Post procedural magnetic resonance imaging (MRI) will be performed at one and three months post trial entry and at three-monthly intervals thereafter for two years to assess tumor response. Primary outcome will be time to progression. Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness.Trial registrationNCT01381211

Clinical and Metabolic Studies of a Low-estrogen Dose Combined Oral Contraceptive in Thai Women

Administration of a low-estrogen combined oral contraceptive containing 0.15 mg d-norgestrel and 30 μg ethinyl estradiol per tablet to 268 Thai women for clinical study and in another group of 13 Thai women for metabolic study provided a satisfactory result. No effect of the treatment was observed on blood pressure, serum triglycerides, total serum cholesterol or liver function. However, minor changes in the body weight, oral glucose tolerance and serum insulin were observed. This oral contraceptive preparation seemed to gain the body weight and to show its acceptability and effectiveness, but a firm conclusion could not be drawn on either of them which was due to a high loss to follow-up in the study.

Nuclear Imaging Techniques for the Assessment of Hepatic Function in Liver Surgery and Transplantation

This review describes the application of 2 nuclear imaging techniques for assessment of hepatic function in the setting of liver surgery and transplantation. The biochemical and technical background, as well as the clinical applications, of (99m)Tc-labeled diethylenetriaminepentaacetic acid galactosyl human serum albumin (GSA) scintigraphy and hepatobiliary scintigraphy (HBS) with (99m)Tc-labeled iminodiacetic acid derivates is discussed. (99m)Tc-mebrofenin is considered the most suitable iminodiacetic acid agent for (99m)Tc-HBS. (99m)Tc-GSA scintigraphy and (99m)Tc-mebrofenin HBS are based on 2 different principles. (99m)Tc-GSA scintigraphy is a receptor-mediated technique whereas HBS represents hepatic uptake and excretion function. Both techniques are noninvasive and provide visual and quantitative information on both total and regional liver function. They can be used for preoperative assessment of future remnant liver function, follow-up after preoperative portal vein embolization, and evaluation of postoperative liver regeneration. In liver transplantation, these methods are used to assess graft function and biliary complications.

Development and validation of a comprehensive new hepatobiliary software. Part II: segmental liver function

This study was undertaken to develop comprehensive new hepatobiliary software to quantify segmental and lobar liver function and to obtain FDA approval. Hepatobiliary software written on JAVA platform and loaded on to a PC accepts 99mTc-HIDA dicom image data transferred from a gamma camera. Liver boundary was determined by threshold-based auto edge detection and liver height at right midclavicular (RMCL) line. Geometric mean area of the physiologic right lobe, physiologic left lobe and total liver area were measured. Segmental liver function was determined using the 5th minute frame as the default (100%). In 24 control participants, mean (+/-SD) liver height at RMCL was 14.7+/-0.12 cm. Geometric mean area of the physiologic right lobe was 116+/-3 cm2, left lobe 96+/-4 cm2, and total liver area 212+/-3 cm. Right upper lobe (segments 7 and 8) contributed 31+/-0.7%, right lower lobe (segments 5 and 6) 34+/-0.6%, left medial (segments 4A and 4B) 24+/-1%, left lateral (segments 2 and 3) 10+/-2%, and caudate lobe (segment 1) 1+/-0.02% of total liver function. In 23 patients, contrast three-dimensional computerized tomographic volume of the right lobe was 1194+/-419 ml, left lobe 434+/-221 ml, and total liver volume 1628+/-490 ml. Right lobe area was 120+/-30 cm2, left lobe (plus caudate) 88+/-29 cm2 with total liver area of 208+/-51 cm. Right upper lobe (segments 7 and 8) contributed 33+/-10%, right lower lobe (segments 5 and 6) 34+/-7%, left medial (segments 4A and 4B) 23+/-6%, left lateral (segments 2 and 3) 9+/-3%, and caudate lobe (segment 1) 1+/-0.4% of total liver function. There was good correlation of RMCL height, and area of right lobe and total liver with computerized tomographic liver volume. Correlation of percentage volume with percentage function was excellent. New FDA approved software provides quantitative assessment of segmental, lobar, and total liver size and function from a planar 99mTc-HIDA cholescintigraphy and may enable universal standardization in nuclear hepatology. Quantification may aid surgeons in the determination of the amount of tissue resection during liver surgery.

Volumetric and Functional Recovery of the Remnant Liver After Major Liver Resection with Prior Portal Vein Embolization

IntroductionPortal vein embolization is an accepted method to increase the future remnant liver preoperatively. The aim of this study was to assess the effect of preoperative portal vein embolization on liver volume and function 3 months after major liver resection. Materials and methodsThis is a retrospective case-control study. Data were collected of patients who underwent portal vein embolization prior to (extended) right hemihepatectomy and of control patients who underwent the same type of resection without prior portal vein embolization. Liver volumes were measured by computed tomography volumetry before portal vein embolization, before liver resection, and 3 months after liver resection. Liver function was assessed by hepatobiliary scintigraphy before and 3 months after liver resection. ResultsTen patients were included in the embolization group and 13 in the control group. Groups were comparable for gender, age, and number of patients with a compromised liver. The mean future remnant liver volume was 33.0 ± 8.0% prior to portal vein embolization in the embolization group and 45.6 ± 9.1% in the control group (p < 0.01). Prior to surgery, there were no significant differences in future remnant liver volume and function between the groups. Three months postoperatively, the mean remnant liver volume was 81.9 ± 8.9% of the initial total liver volume in the embolization group and 79.4 ± 11.0% in the control group (p > 0.05). Remnant liver function increased up to 88.1 ± 17.4% and 83.3 ± 14% respectively of the original total liver function (p > 0.05). ConclusionPreoperative portal vein embolization does not negatively influence postoperative liver regeneration assessed 3 months after major liver resection.

Inhibitory Effect of Curcumin on Early Liver Regeneration Following Partial Hepatectomy in Rats

Curcumin (Cur) is a nontoxic, hepatoprotective antioxidant. Recent investigations have demonstrated a protective effect of curcumin pretreatment during cold ischemia of hepatocytes, but its impact on liver regeneration per se has not been investigated so far. Male Sprague-Dawley rats (n = 6 per group) underwent sham operation, 70% partial hepatectomy (PH), or PH with curcumin application (100 mg per kg bodyweight per day) starting 48 h before surgery. Rats were sacrificed 24 h after surgery. Liver regeneration was analyzed by measurement of relative liver weight, mitotic-index, bromo-deoxy-uridine (BrdU)-incorporation and Ki-67 expression. The relative liver weight 24 h after surgery was similar in the PH groups with and without curcumin treatment. Also, a comparably high number of Ki-67 positive proliferating hepatocytes was detected in both groups. In contrast, the mitotic index in the untreated PH group (83 +/- 20 mitosis/2000 hepatocytes) was significantly higher than in the curcumin treated group (21 +/- 6). The BrdU labeling index was slightly higher in the curcumin treated group with PH (24% +/- 5%) than in the untreated group (16% +/- 2%). The hepatocyte density as marker of cellular hypertrophy was significantly lower in the curcumin group (474 +/- 23) than in the untreated group (609 +/- 22). Curcumin inhibits cell cycle progression during normal liver regeneration in rats, predominantly at the level of the G2/M transition point. However, the total liver mass and function was not significantly altered. Nevertheless, application of curcumin in conditions of high physiological cell proliferation should be performed with caution.

Comparative Study of Portal Vein Embolization Versus Portal Vein Ligation for Induction of Hypertrophy of the Future Liver Remnant Using a Mini-Pig Model

The extent of hepatectomies is limited by the functional reserve of the remnant liver. The introduction of preoperative portal vein occlusion techniques to induce a preoperative hyperplasia of the future liver remnant has reduced the risk of postoperative liver failure. However, it has remained a matter of debate whether partial portal vein embolization (PVE) or suture ligation of the portal branches during exploration is the preferred technique. We compared both techniques under standardized experimental conditions in a large animal model by means of effectiveness and pathophysiologic differences. Thirteen mini-pigs underwent portal vein ligation (PVL), 11 mini-pigs underwent PVE of 75% of the liver volume, and 6 underwent a sham operation. The animals were killed after 28 days. Laboratory liver function and damage parameters, lobar liver-to-body weight indices, portal and arterial flow alterations, and histologic changes were assessed. Ex situ arteriograms and portograms were performed to examine adaptive changes in the macroarchitecture of both vascular systems. The liver-to-body weight index of the nonoccluded lobe was highest after PVE (0.85) versus 0.6 (P < 0.05) after PVL. There was no significant reduction in global serum parameters reflecting total liver function. After 4 weeks, the PVL group consistently exhibited hepatopetal portal flow in the ligated lobes, which was present but significantly decreased after PVE. The ex situ angiography after PVE and PVL revealed the development of portal neocollaterals in the portal-occluded liver parts. Both PVL and PVE are able to induce hypertrophy of the future liver remnant. In comparison, PVE is the more effective technique to increase the future liver remnant. This is due to a more effective, durable occlusion of the portal branches. Formation of collaterals between occluded and nonoccluded liver parts seems to be the cause of inferior regeneration in the ligation group.

Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study

The effects of pioglitazone on sildenafil responsiveness in men with erectile dysfunction(ED) and a history of poor response to sildenafil were assessed. In a double-blinded study,38 men aged 47 +/- 1.5 years with moderate-to severe ED and poor response to sildenafil were randomly assigned to take a premedication of pioglitazone 30 mg (n=19) or placebo (n=19) once daily for 9 weeks along with on-demand use of sildenafil during the last month of pioglitazone treatment.Erectile function (EF) scores, assessed by EF domain of International Index of Erectile Function (IIEF), along with responses to Global Assessment Questions (GAQs) were major outcome measures. Serum levels of total testosterone (T),dehydroepiandrosterone sulfate (DHEAS), glucose,lipid profile and liver function test were minor outcome measures. Pioglitazone significantly improved major outcome measures compared with placebo. The decrease from baseline of total cholesterol level was more in pioglitazone than in placebo-treated groups. In 84% (32 out of 38) of the sildenafil poor-responders, at least one of the associated risk factors of ED was found. There was undiagnosed hypercholesterolemia in 34% of the subjects. Serum levels of T, DHEAS, glucose and other parameters remained unchanged in both groups. The intervention was well tolerated. Pioglitazone increased sildenafil response to improve ED of men with prior sildenafil failure and seems to be safe based on the present preliminary study. This improvement is likely regardless of fasting glucose and sex hormones levels.

Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies

of results 229 patients (pts) were included. Mean age was 37 years. Most pts (54%) were former intravenous drug users. 135 individuals were co-infected with HCV. Median time on NVP was 72.6 months. The main reasons to use NVP were: second or third-line therapy (40%), simplification (30%), first-line therapy (19%), and efavirenz intolerance (10%). Combinations of nucleosides most widely used were: ABC+3TC (25%), AZT+3TC (23%) and TDF+3TC (14%). HDL-cholesterol and GGT increased from baseline to >4year timepoint (48 mg/dl to 62 mg/dl and 58 U/l to 145 U/l, respectively). LDL-cholesterol, triglycerides and alkaline phosphatase showed decreasing values at follow-up (135 mg/dl to 109 mg/dl, 216 to 153 mg/dl, and 177 to 92, respectively). Total cholesterol and liver function tests had no significant changes. CD4 cell counts increased from 439/mm3 at baseline to 628/mm3 at the last available visit. 172 out of 184 pts who remained on NVP-based therapy at last visit maintained viral load values below limit of detection. NVP was stopped or withdrawn in 43 patients due to virological failure (13 pts), toxicity (five pts), virological resistance (four pts), therapy interruption (three pts), death (two pts), dyslipidemia (one pt), simplification (one pt) or unknown reasons (14 pts). Adverse events were reported in 40 patients but none was directly attributed to NVP. The reported follow-up pattern of laboratory tests was also found in the subset of HCV coinfected patients by comparing men and women and stratifying patients with a CD4 cell count cut-off value of 250/mm3.

A case of Churg–Strauss syndrome undergoing radical mastectomy under general anaesthesia and thoracic epidural analgesia

A case of Churg–Strauss syndrome undergoing radical mastectomy under general anaesthesia and thoracic epidural analgesia

Imaging of liver function with dedicated animal dynamic pinhole scintigraphy in rats

Non-invasive evaluation of liver function in small animal models remains a challenge. Hepatobiliary scintigraphy (HBS) enables the assessment of total and regional liver function for both uptake and excretion in larger species. To validate quantitative liver function assessment with dedicated pinhole HBS in rats. To illustrate an application of this technique, liver function was assessed in two surgical models of liver regeneration. HBS was performed in 12 rats with 99mTc-mebrofenin on a dedicated animal pinhole gamma camera. The hepatic uptake rate was calculated twice by different observers to establish a normal range and the reproducibility of processing. The degree of hepatocellular injury and synthesis function were assessed by serum liver tests. Liver function was compared with liver weight. Subsequently, three groups of three rats were scanned on three separate days to assess the reproducibility of HBS. Finally, to illustrate an application of this technique, liver function was assessed in two surgical models of liver regeneration. HBS in rats was feasible without mortality. The mean liver uptake rate was 77.29+/-1.29% . min(-1). Calculation of the liver uptake (% . min(-1)) was highly reproducible (r=0.95, P<0.001). There was a good correlation between liver weight and function measured by HBS at baseline and after partial resection (r=0.94, P<0.001). HBS offers a unique combination of functional liver uptake and excretion assessment with the ability to determine the liver function reserve before and after an intervention in rats.

An unusual presentation of body cavity lymphoma

6699 Background: BCL (Body Cavity Lymphoma) is an uncommon primary NHL (Non-Hodgkin's lymphoms) that proliferates within serous body cavities - pleural, pericardial or peritoneal, resulting in recurrent effusions. It is common in young to middle-aged HIV (Human Immunodeficiency Virus) positive homosexual males. In the absence of HIV infection, it almost universally develops in the background of HHV-8/KSHV (Human Herpes Virus-8/ Kaposi's Sarcoma Herpes Virus) infection with or without EBV (Epstein Barr Virus). Rare BCLs have been reported in elderly populations, which are both HIV negative and HHV-8 negative. We report an unusual case of BCL, which is HHV-8 negative and EBV positive. Abstract: 75 yrs old Immigrant Ashkenazi Jew from Russia was admitted with shortness of breath for 1 month and leg edema. No B-symptoms. His Karnofsky performance status was 80. He is heterosexual, monogamous, non-smoker and denied alcohol or intravenous drug abuse. Clinical examination revealed a right-sided pleural effusion only. Complete Blood Count showed mild normocytic normochromic anemia with hemoglobin -11.5 gm/dl. Total white count, differential, renal and liver function tests were normal. Serum LDH 200 U/L, serum β2 Microglobulin 2.8. Pleural fluid was frankly hemorrhagic with 80,000 RBC/cu mm, 16,800 WBC/ cu mm with 65% lymphocytes and 26% monocytes. Pleural fluid LDH 4500 U/L and cytology revealed Large cell lymphoma. CT scan of chest, abdomen and pelvis failed to demonstrate any lymphadenopathy or organomegaly. There was no pericardial effusion or ascites. Pleural fluid flow-cytometry demonstrated monoclonal lambda B-cell population lacking CD5 or CD10. The cells were positive for CD19, CD20, CD22 and CD45 and negative for CD2, CD3, CD4, CD5, CD7, CD9, CD10, CD11c and CD13/33. Bone marrow aspiration biopsy and flow-cytometry were negative for disease. Serum PCR for HHV-8, Human T Cell Leukemia Virus 1 and 2, Hepatitis C Virus negative, serum EBV IgG positive. CD4 count was 400 and CD8 was 300 with a ratio of 1.3. A diagnosis of BCL was made. He underwent therapeutic thoracentesis with relief of respiratory symptoms.Standard CHOP-like chemotherapy has been planned for this patient. No significant financial relationships to disclose.

An unusual presentation of body cavity lymphoma

6699 Background: BCL (Body Cavity Lymphoma) is an uncommon primary NHL (Non-Hodgkin's lymphoms) that proliferates within serous body cavities - pleural, pericardial or peritoneal, resulting in recurrent effusions. It is common in young to middle-aged HIV (Human Immunodeficiency Virus) positive homosexual males. In the absence of HIV infection, it almost universally develops in the background of HHV-8/KSHV (Human Herpes Virus-8/ Kaposi's Sarcoma Herpes Virus) infection with or without EBV (Epstein Barr Virus). Rare BCLs have been reported in elderly populations, which are both HIV negative and HHV-8 negative. We report an unusual case of BCL, which is HHV-8 negative and EBV positive. Abstract: 75 yrs old Immigrant Ashkenazi Jew from Russia was admitted with shortness of breath for 1 month and leg edema. No B-symptoms. His Karnofsky performance status was 80. He is heterosexual, monogamous, non-smoker and denied alcohol or intravenous drug abuse. Clinical examination revealed a right-sided pleural effusion only. Complete Blood Count showed mild normocytic normochromic anemia with hemoglobin -11.5 gm/dl. Total white count, differential, renal and liver function tests were normal. Serum LDH 200 U/L, serum β2 Microglobulin 2.8. Pleural fluid was frankly hemorrhagic with 80,000 RBC/cu mm, 16,800 WBC/ cu mm with 65% lymphocytes and 26% monocytes. Pleural fluid LDH 4500 U/L and cytology revealed Large cell lymphoma. CT scan of chest, abdomen and pelvis failed to demonstrate any lymphadenopathy or organomegaly. There was no pericardial effusion or ascites. Pleural fluid flow-cytometry demonstrated monoclonal lambda B-cell population lacking CD5 or CD10. The cells were positive for CD19, CD20, CD22 and CD45 and negative for CD2, CD3, CD4, CD5, CD7, CD9, CD10, CD11c and CD13/33. Bone marrow aspiration biopsy and flow-cytometry were negative for disease. Serum PCR for HHV-8, Human T Cell Leukemia Virus 1 and 2, Hepatitis C Virus negative, serum EBV IgG positive. CD4 count was 400 and CD8 was 300 with a ratio of 1.3. A diagnosis of BCL was made. He underwent therapeutic thoracentesis with relief of respiratory symptoms.Standard CHOP-like chemotherapy has been planned for this patient. No significant financial relationships to disclose.

Binding rate constant of Tc-99m DTPA galactosyl human serum albumin measured by quantitative dynamic SPECT--clinical evaluation as a total and regional liver function test.

To evaluate the clinical utility of a new method with dynamic single photon emission computed tomography (SPECT) and scatter and attenuation compensation to estimate both total and regional liver function quantitatively. Five controls, 20 patients with chronic liver disease, and 2 patients with Budd-Chiari syndrome were studied. Dynamic liver SPECT data were acquired during 20 minutes after injection of Technetium (Tc)-99m diethylenetriaminepentaacetic acid (DTPA) galactosyl human serum albumin (GSA) with scatter and attenuation compensation. The binding rate constant of Tc-99m GSA (Ku) was derived quantitatively from the Patlak plot based on kinetic models for GSA receptor binding. The mean Ku was obtained by dividing the Ku value (total Ku) by the liver volume. Both total and mean Ku were significantly lower in patients with chronic liver disease than in controls (302 +/- 112 vs. 523 +/- 78 ml/min; p < 0.001, 0.26 +/- 0.11 vs. 0.43 +/- 0.03 ml/min/cm3; p < 0.001). In the patient group, both total and mean Ku were significantly correlated with the results of conventional liver function tests and the histological severity of chronic liver disease. In 2 patients with Budd-Chiari syndrome, the mean Ku was lower in the right lobe, where the hepatic veins were occluded, than in the left lobe, where draining veins were patent. In conclusion, this method is a reliable diagnostic technique for estimating total and regional liver function.